Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice-Reference-Cited by-同舟云学术

Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice

Published:2012-12 Issue:4 Volume:11 Page:229-237
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Ficorella Corrado,Bruera Gemma,Cannita Katia,Porzio Giampiero,Baldi Paola Lanfiuti,Tinari Nicola,Natoli Clara,Ricevuto Enrico

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference57 articles.

1. Fluorouracil in colorectal cancer–a tale of two drugs: implications for biochemical modulation;Sobrero;J Clin Oncol,1997

2. Moving beyond fluorouracil for colorectal cancer;Mayer;N Engl J Med,2000

3. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma;Machover;Cancer,1997

4. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer;Saltz;N Engl J Med,2000

5. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial;Douillard;Lancet,2000

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer;JCO Oncology Practice;2021-12

2. Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice;Annals of Translational Medicine;2021-06

Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

;Pharmacogenomics and Personalized Medicine;2020-11

4. Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy;Frontiers in Oncology;2020-08-04

5. Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease;Frontiers in Oncology;2020-02-20